Adma Biologics Inc (ADMA) live share price

Adma Biologics Inc share price in USD $20.11 & INR ₹1,700.08

$20.11

▲

-1.72

(-7.88%)

View live Adma Biologics Inc share price in Dollar and Rupees. Guide to invest in Adma Biologics Inc from India. Also see the sentimental analysis on Indian investors investing in Adma Biologics Inc. Get details on the Indian mutual funds that are investing in Adma Biologics Inc. Get Analyst recommendations and forecasts along with all the Adma Biologics Inc's financials.

Adma Biologics Inc share price movements

$19.77
$21.72
$20.11
1.69%
Downside
Day's Volatility :8.98%
Upside
7.41%
$3.60
$23.64
$20.11
82.1%
Downside
52 Weeks Volatility :84.77%
Upside
14.93%

Adma Biologics Inc Returns

Period	Adma Biologics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	21.36%	-6.2%	0.0%
6 Months	104.99%	2.6%	0.0%
1 Year	418.3%	11.8%	0.0%
3 Years	890.64%	13.8%	-17.6%

Adma Biologics Inc Key Statistics

in dollars & INR

Market Capitalization	$4.8B
Revenue TTM	$382.8M
EBITDA	$125.9M
Earnings Per Share (EPS)	$0.27
PE Ratio	74.48
Profit Margin	17.8%
Quarterly Earnings Growth YOY	14.0%
Return On Equity TTM	35.55%

How to invest in Adma Biologics Inc from India?

It is very easy for Indian residents to invest directly in Adma Biologics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Adma Biologics Inc stock in both rupees (INR) and dollars (USD). Search for Adma Biologics Inc or ADMA on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Adma Biologics Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Adma Biologics Inc shares which would translate to 0.042 fractional shares of Adma Biologics Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Adma Biologics Inc

-25.0%

Period: Sep 2, 2024 to Dec 1, 2024. Change in 30 Days versus previous period

Investment in Adma Biologics Inc from India has reduced in the last 30 days as on Dec 2, 2024. -25.0% less purchase transactions for Adma Biologics Inc in the last 30 days versus the previous period.

33%

Period: Sep 2, 2024 to Dec 1, 2024. Change in 30 Days versus previous period

Search volume for Adma Biologics Inc on INDmoney from India has grown in the last 30 days as on Dec 2, 2024. 33% more investors are searching Adma Biologics Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Adma Biologics Inc

BlackRock Inc
7.89%
Vanguard Group Inc
7.67%
Amvescap Plc.
5.57%
Morgan Stanley - Brokerage Accounts
3.89%
Nuveen Asset Management, LLC
3.78%
State Street Corp
3.41%

Analyst Recommendation on Adma Biologics Inc

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Adma Biologics Inc(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Adma Biologics Inc

What analysts predicted

Upside of 16.59%

Current:

$20.11

Target:

$23.45

Insights on Adma Biologics Inc

Increasing Revenue
Revenue is up for the last 18 quarters, 7.78M → 119.83M (in $), with an average increase of 14.6% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -17.64M → 35.90M (in $), with an average increase of 84.8% per quarter

Adma Biologics Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$17.0M	↓ 25.37%
Net Income	$-65.7M	↑ 50.24%
Net Profit Margin	-387.06%	↓ 194.8%

	FY19	Y/Y Change
Revenue	$29.3M	↑ 72.79%
Net Income	$-57.0M	↓ 13.23%
Net Profit Margin	-194.37%	↑ 192.69%

	FY20	Y/Y Change
Revenue	$42.2M	↑ 43.85%
Net Income	$-87.6M	↑ 53.57%
Net Profit Margin	-207.5%	↓ 13.13%

	FY21	Y/Y Change
Revenue	$80.9M	↑ 91.72%
Net Income	$-84.5M	↓ 3.6%
Net Profit Margin	-104.34%	↑ 103.16%

	FY22	Y/Y Change
Revenue	$154.1M	↑ 90.36%
Net Income	$-85.2M	↑ 0.86%
Net Profit Margin	-55.29%	↑ 49.05%

	FY23	Y/Y Change
Revenue	$258.2M	↑ 67.59%
Net Income	$-28.2M	↓ 66.85%
Net Profit Margin	-10.94%	↑ 44.35%

	Q2 FY23	Q/Q Change
Revenue	$60.1M	↑ 5.64%
Net Income	$-6.4M	↓ 50.09%
Net Profit Margin	-10.6%	↑ 11.83%

	Q3 FY23	Q/Q Change
Revenue	$67.3M	↑ 11.89%
Net Income	$2.6M	↓ 140.26%
Net Profit Margin	3.81%	↑ 14.41%

	Q4 FY23	Q/Q Change
Revenue	$73.9M	↑ 9.85%
Net Income	$-17.6M	↓ 787.88%
Net Profit Margin	-23.88%	↓ 27.69%

	Q1 FY24	Q/Q Change
Revenue	$81.9M	↑ 10.79%
Net Income	$17.8M	↓ 200.92%
Net Profit Margin	21.75%	↑ 45.63%

	Q2 FY24	Q/Q Change
Revenue	$107.2M	↑ 30.92%
Net Income	$32.1M	↑ 80.06%
Net Profit Margin	29.91%	↑ 8.16%

	Q3 FY24	Q/Q Change
Revenue	$119.8M	↑ 11.8%
Net Income	$35.9M	↑ 12.0%
Net Profit Margin	29.96%	↑ 0.05%

	FY18	Y/Y Change
Total Assets	$88.9M	↓ 17.72%
Total Liabilities	$69.1M	↑ 2.1%

	FY19	Y/Y Change
Total Assets	$127.1M	↑ 43.0%
Total Liabilities	$100.9M	↑ 46.0%

	FY20	Y/Y Change
Total Assets	$207.7M	↑ 63.41%
Total Liabilities	$119.4M	↑ 18.36%

	FY21	Y/Y Change
Total Assets	$276.3M	↑ 33.02%
Total Liabilities	$135.1M	↑ 13.11%

	FY22	Y/Y Change
Total Assets	$348.5M	↑ 26.14%
Total Liabilities	$196.5M	↑ 45.46%

	FY23	Y/Y Change
Total Assets	$329.2M	↓ 5.53%
Total Liabilities	$194.0M	↓ 1.28%

	Q2 FY23	Q/Q Change
Total Assets	$343.0M	↑ 0.66%
Total Liabilities	$196.3M	↑ 0.58%

	Q3 FY23	Q/Q Change
Total Assets	$349.0M	↑ 1.74%
Total Liabilities	$197.6M	↑ 0.66%

	Q4 FY23	Q/Q Change
Total Assets	$329.2M	↓ 5.68%
Total Liabilities	$194.0M	↓ 1.81%

	Q1 FY24	Q/Q Change
Total Assets	$350.9M	↑ 6.59%
Total Liabilities	$197.2M	↑ 1.65%

	Q2 FY24	Q/Q Change
Total Assets	$376.4M	↑ 7.27%
Total Liabilities	$188.1M	↓ 4.58%

	Q3 FY24	Q/Q Change
Total Assets	$390.6M	↑ 3.78%
Total Liabilities	$158.7M	↓ 15.63%

	FY18	Y/Y Change
Operating Cash Flow	$-62.7M	↑ 68.17%
Investing Cash Flow	$-2.1M	↓ 113.77%
Financing Cash Flow	$42.9M	↓ 29.35%

	FY19	Y/Y Change
Operating Cash Flow	$-76.2M	↑ 21.56%
Investing Cash Flow	$-3.8M	↑ 81.9%
Financing Cash Flow	$80.0M	↑ 86.39%

	FY20	Y/Y Change
Operating Cash Flow	$-102.0M	↑ 33.87%
Investing Cash Flow	$-12.7M	↑ 233.82%
Financing Cash Flow	$143.9M	↑ 79.86%

	FY21	Y/Y Change
Operating Cash Flow	$-112.4M	↑ 10.16%
Investing Cash Flow	$-13.5M	↑ 6.18%
Financing Cash Flow	$121.0M	↓ 15.88%

	FY22	Y/Y Change
Operating Cash Flow	$-59.5M	↓ 47.04%
Investing Cash Flow	$-13.9M	↑ 2.96%
Financing Cash Flow	$108.9M	↓ 10.08%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.1M	↓ 58.85%
Investing Cash Flow	$-872.6K	↓ 55.13%
Financing Cash Flow	$240.1K	↓ 136.91%

Adma Biologics Inc Technicals Summary

Sell

Neutral

Buy

Adma Biologics Inc is currently in a neutral trading position according to technical analysis indicators.

Adma Biologics Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adma Biologics Inc	5.23%	104.99%	418.3%	890.64%	890.64%
Regeneron Pharmaceuticals, Inc.	-11.07%	-24.18%	-8.88%	18.12%	102.78%
Biontech Se	6.2%	15.09%	18.5%	-65.59%	454.0%
Alnylam Pharmaceuticals, Inc.	-7.61%	68.21%	46.39%	47.68%	107.47%
Vertex Pharmaceuticals Incorporated	-0.63%	-0.44%	33.51%	129.69%	109.07%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adma Biologics Inc	74.48	74.48	0.0	0.51	0.36	0.2	NA	0.98
Regeneron Pharmaceuticals, Inc.	18.66	18.66	1.12	44.91	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.22	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adma Biologics Inc	Buy	$4.8B	890.64%	74.48	17.8%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	102.78%	18.66	33.61%
Biontech Se	Buy	$28.9B	454.0%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	107.47%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$119.6B	109.07%	32.84	-4.51%

About Adma Biologics Inc

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Organization	Adma Biologics Inc
Employees	624
CEO	Mr. Adam S. Grossman
Industry	Health Technology

Important FAQs about investing in Adma Biologics Inc from India :

What is Adma Biologics Inc share price today?

Adma Biologics Inc (ADMA) share price today is $20.11.

Can Indians buy Adma Biologics Inc shares?

Yes, Indians can invest in the Adma Biologics Inc (ADMA) from India.

With INDmoney, you can buy Adma Biologics Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Adma Biologics Inc at zero transaction cost.

How can I buy Adma Biologics Inc shares from India?

It is very easy to buy Adma Biologics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Adma Biologics Inc be purchased?

Yes, you can buy fractional shares of Adma Biologics Inc with INDmoney app.

What are the documents required to start investing in Adma Biologics Inc stocks?

To start investing in Adma Biologics Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.